Inactive Instrument

Chinook Therapeutics, Inc.

Equities

KDNY

US16961L1061

Biotechnology & Medical Research

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Chinook Therapeutics, Inc. Announces Board Cessations CI
Novartis Says it Completed Chinook Therapeutics Acquisition MT
Novartis Completes Acquisition of Chinook Therapeutics for Up to $3.5 Billion MT
Chinook Therapeutics, Inc.(NasdaqGM:KDNY) dropped from NASDAQ Composite Index CI
Novartis AG completed the acquisition of Chinook Therapeutics, Inc. from a group of shareholders. CI
Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from S&P Global BMI Index CI
Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from S&P TMI Index CI
Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from S&P Biotechnology Select Industry Index CI
North American Morning Briefing : Traders Absorb -2- DJ
Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from NASDAQ Biotechnology Index CI
Wedbush Downgrades Chinook Therapeutics to Neutral From Outperform as Sale to Novartis Draws Closer; Keeps $42 Price Target MT
Chinook Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
North American Morning Briefing : Stock Futures -2- DJ
Wells Fargo Downgrades Chinook Therapeutics to Equalweight From Overweight, Adjusts Price Target to $40 From $30 MT
ANALYST RECOMMENDATIONS : Meta, Thermo Fisher, Union Pacific, Domino's Pizza... Our Logo
Chinook Therapeutics Says First Patient Enrolled in Phase 3 Trial of Zigakibart to Treat IgA Nephropathy MT
Chinook Therapeutics, Inc. Announces the First Patient Enrolled in its Phase 3 Second Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy CI
Chinook Therapeutics, Inc.(NasdaqGS:KDNY) added to Russell 3000E Growth Index CI
Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from Russell 3000E Index CI
Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from Russell Microcap Index CI
Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from Russell Microcap Value Index CI
Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from Russell 3000E Value Index CI
Chinook Therapeutics, Inc.(NasdaqGS:KDNY) added to Russell 3000 Growth Index CI
Chinook Therapeutics, Inc.(NasdaqGS:KDNY) added to Russell 2500 Growth Index CI
Chinook Therapeutics, Inc.(NasdaqGS:KDNY) added to Russell Small Cap Comp Growth Index CI
Chart Chinook Therapeutics, Inc.
More charts
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing precision medicines for kidney diseases. Its lead product candidate is atrasentan, a potent and selective endothelin A receptor (ET A receptor), antagonist that is developing for the treatment of proteinuric glomerular diseases. Atrasentan is in Phase III trials for the treatment of IgA nephropathy (IgAN) and proteinuric glomerular diseases. Its second product candidate, BION-1301, is an anti-APRIL monoclonal antibody also in Phase II development for patients with IgAN. Its third product candidate, CHK-336, is an oral small molecule lactate dehydrogenase (LDHA), inhibitor for the treatment of primary and idiopathic hyperoxaluria that is in a Phase I clinical trial in healthy volunteers. In addition, the Company is also conducting research programs in several other rare, severe chronic kidney diseases.
More about the company
  1. Stock
  2. Equities
  3. Stock Chinook Therapeutics, Inc. - Nasdaq
  4. News Chinook Therapeutics, Inc.
  5. Wells Fargo Starts Chinook Therapeutics at Overweight With $30 Price Target